Pierre Fumoleau, MD

home / authors / pierre-fumoleau-md

Articles

UFT/Leucovorin Plus Vinorelbine Combination for Advanced Breast Cancer

Pierre Fumoleau, MD;Régine Déporte, PhD;Pierre Kerbrat, MD;Jacques M. Bonneterre, MD, PhD;Pierre Fargeot, MD

October 1st 2000

This phase I study was undertaken to define the maximum tolerated dose, the dose-limiting toxicity, and the recommended dose of UFT plus leucovorin and vinorelbine in combination treatment of patients with metastatic breast cancer previously treated with one chemotherapy regimen. The pharmacokinetics of UFT and vinorelbine were also evaluated.

UFT Plus Oral Calcium Folinate/Vinorelbine for Advanced Breast Cancer

Pierre Fumoleau, MD;Régine Déporte-Fety, PhD;Pierre Kerbrat, MD;Brigitte Laguerre, MD

July 1st 1999

This phase I study was undertaken to define the maximum tolerated dose, dose-limiting toxicity, and recommended dosage of UFT (uracil and tegafur) plus oral calcium folinate (Orzel) and vinorelbine (Navelbine) in

Docetaxel Combined With Vinorelbine: Phase I Results and New Study Designs

Pierre Fumoleau, MD;Valerie Delecroix, MD;Regine Féty, PhD;Nacer Azli, MD

June 1st 1997

This was a phase I dose-finding and pharmacokinetic study of vinorelbine (Navelbine) and docetaxel (Taxotere) as first-line chemotherapy for metastatic breast cancer. Vinorelbine dose, 20 or 22.5 mg/m², on days 1 and 5, was followed on day 1 by docetaxel every 21 days, in doses increasing from 60 to 100 mg/m².